Added on 09/22/07
In this developed world, obesity has become the chronic condition linked with higher risk factors of cardiovascular disorders. The obesity around abdominal area particularly increases the risk of diabetes, heart attacks and untimely death in some...
See more 
In this developed world, obesity has become the chronic condition linked with higher risk factors of cardiovascular disorders. The obesity around abdominal area particularly increases the risk of diabetes, heart attacks and untimely death in some cases. The smokers are more prone to such risks anyway. Sanofi-Synthelabo, the subsidiary of world renowned pharmaceutical giants Sanofi-Aventis have introduced a wonder formulation known as Rimonabant for treating the obesity. For those who are overweight may be greatly helped losing weight by using Rimonabant pills. Rimonabant is the anorectic anti-obesity, CB1 Cannabinoid receptor antagonist medication. The most vital key of its effect is diminution in craving. It is the first selective CB1 receptor blocker being approved for use as anti-obesity drug. The drug, in European Union nations, has been directed for use in combination with diet and exercise especially for having BMI of over 30kg/cm2 or patients having BMI of 27kg/cm2 or more with... See less 
